94 results
Page 4 of 5
8-K
EX-99.1
dc0ap8aeew
22 Feb 21
Pulse Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results
4:18pm
8-K
EX-99.1
w57fco9a4pawugxk
4 Feb 21
Pulse Biosciences, Inc. Announces At-The-Market Equity Offering Program
8:30am
8-K
EX-99.1
7xls1ounwppb5lx
3 Feb 21
Pulse Biosciences Announces FDA Clearance for the CellFX® System
4:13pm
8-K
EX-99.1
yzphh0n
25 Jan 21
Pulse Biosciences Announces CE Mark Approval for CellFX® System
8:12am
8-K
EX-99.1
asa6e95vcv
5 Jan 21
Pulse Biosciences, Inc. Announces Redemption of Warrants
9:16am
8-K
EX-99.1
5mfisnutcwas16fhy2
9 Nov 20
Pulse Biosciences Reports Third Quarter 2020 Financial Results
4:29pm
8-K
EX-99.1
k252y
10 Aug 20
Pulse Biosciences Reports Second Quarter 2020 Financial Results
4:27pm
8-K
EX-99.1
l92kjykhjdup
6 Aug 20
Pulse Biosciences, Inc. Appoints Richard van den Broek to Board of Directors
5:00pm
8-K
EX-99.1
5u4pwy07saeiipj3sp47
17 Jun 20
Pulse Biosciences, Inc. Announces Closing of $30 Million Rights Offering
12:00am
8-K
EX-99.1
bmn9ug yuwehn5z40
9 Jun 20
Pulse Biosciences, Inc. Announces Preliminary Results for Its Oversubcribed Rights Offering
12:00am
8-K
EX-99.1
71rik
15 May 20
Pulse Biosciences, Inc. Announces Commencement of Rights Offering
12:00am
8-K
EX-99.1
yqq4n8jk
11 May 20
Pulse Biosciences Reports First Quarter 2020 Financial Results
4:16pm
8-K
EX-99.1
rzb17xrl aip8x
1 May 20
Pulse Biosciences, Inc. Announces Updated Structure, Dates and Pricing Terms for Rights Offering
9:15am
8-K
EX-99.1
aj3md lm67kp0w
6 Apr 20
Pulse Biosciences files Registration Statement for Rights Offering
9:15am
8-K
EX-99.1
erl6vr
16 Mar 20
Pulse Biosciences Report Fourth Quarter and Full Year 2019 Financial Results
4:32pm